Say NO to ACTA

Uploaded by laquadrature on 27 Oct 2011

Negotiated in secret by 39 countries, ACTA is one more offensive against the sharing of culture on the Internet. Officially The Anti-Counterfeiting Trade Agreement (ACTA) is a proposed plurilateral agreement for the purpose of establishing international standards on intellectual property rights enforcement. ACTA would establish a new international legal framework that countries can join on a voluntary basis and would create its own governing body outside existing international institutions. Negotiating countries have described it as a response "to the increase in global trade of counterfeit goods and pirated copyright protected works. The scope of ACTA includes counterfeit goods, generic medicines and copyright infringement on the Internet."

A signing ceremony was held on 1 October 2011 in Tokyo, with the United States, Australia, Canada, Japan, Morocco, New Zealand, Singapore, and South Korea signing the treaty. The European Union, Mexico, and Switzerland did not sign the treaty, but "attended the ceremony and confirmed their continuing strong support for and preparations to sign the Agreement as soon as practicable." Article 39 of ACTA specifies that the agreement is open for signature until 31 March 2013.

http://en.wikipedia.org/wiki/Anti-Counterfeiting_Trade_Agreement

Learn more and take action about ACTA at
http://lqdn.fr/ACTA
(subtitles included : fr, en, es)

Here are few ways to act against ACTA, right now: http://www.laquadrature.net/wiki/How_to_act_against_ACTA

Origins of Medical Industry Corruption

Uploaded by BrewedStrange on 13 May 2010

The modern day mainstream medical industry has a dubious history, deeply rooted by a drive for profit through the subversion and suppression of non-profitable and non-patentable therapies and treatments.

To this day mainstream allopathic doctors and practitioners are heavily indoctrinated into a system that protects ever increasing industry profits while fiercely defending orthodox therapies. The network of allopathic medical institutions and education strictly denies medical freedom and outlaws any treatments that cannot generate market share profits for their monopolized industry.

Prop 19 - the Hidden Agenda pt3

...Pt1 - Monsanto Marijuana HERE...

...Pt2 - Meet Dr Frankenbeanstein HERE...
...Pt3 - the Patent Plot & the Sativex Connection ...

During the last decade a split has developed within the marijuana community. One group is comprised of those who believe that the community's interests are best served by patenting marijuana strains and marijuana medicines in order to make them safer, more effective, more legitimate, more understood or, perhaps most importantly, more readily accessible since they will be legally available. The other group consists of those who believe that smoked cannabis is the "gold standard" ; the safest, cheapest and, largely because of the ease with which it can be titrated, the most effective form cannabis medicine will take. This second group denies any real advantage of marijuana patents to the consumer, challenges any claim of exclusive rights of the first group to sell a particular strain and opposes the exploitation of a combination of patents and prohibition to force consumers to settle for an inferior product.

Within the first group we find those such as Britain's GW Pharmaceutical, who (with the help of pharmaceutical-giant Bayer) is now selling their whole-plant cannabis spray Sativex. This group also includes the Toronto-based Cannasat Therapeutics, The Nevada-based Dynamic Alert Ltd and various other smaller operations. These companies are looking to patent cannabis medicines, strains of cannabis or both - if they haven't already done so.

In July 1998, Speaking at the International Cannabinoid Research Society conference in Montpellier, Dr Geoffrey W Guy, Chairman of GW Pharmaceuticals, said that HortaPharm will provide GW with exclusive access to its entire range of cannabis varieties for the development of medicines. The worldwide rights acquired by GW for an undisclosed sum cover varieties grown to date with certain exceptions and all varieties to be bred in the future. Plant registrations arising from the Dutch breeding program will be owned by GW pharmaceutical.

Under the agreement GW Pharma will be responsible for the development of specific drug delivery technologies to administer the pharmaceutical grade medicinal cannabis. This work will include a vaporizer for which HortaPharm has a patent pending.

In addition GW Pharma will fund HortaPharm's botanical research and HortaPharm scientists will assist in the UK Glasshouse propagation, cloning and cultivation program.

David Watson, CEO of HortaPharm has stated “As soon as Dr Guy's clinical research indicates the exact desired composition our scientists can breed and register new medicinal varieties".

In May of 2003, GW Pharma and Bayer Incorporated had reached a Marketing Agreement on Pioneering a New cannabis-based medicinal extract product called Sativex.

Bayer reportedly paid $60 Million to GW Pharma to obtain exclusive rights to market Sativex in the UK, And reportedly paid $14 Million for the marketing rights in Canada.

“Bayer corporation is also one of the largest biotechnology and GM producers in the world and has brought to market genetically engineered strains of rice, corn, rapeseed, and canola. Bayer is the world's leading pesticide manufacturer and the world's seventh largest seed company. Bayer CropScience is responsible for the majority of GM field trials in European countries. Bayer's GM crops are mostly "Liberty Link" - designed to be resistant to its "Liberty" herbicide. In 1925, Bayer was one of the chemical companies that merged to form the massive German conglomerate IG Farben, which was the largest single company in Germany and it became the single largest donor to Hitler's election campaign. After Hitler came to power, IG Farben worked in close collaboration with the Nazis, becoming the largest profiteer from the Second World War.”
SEE: http://www.gmwatch.org/gm-firms/11153-bayer-a-history

“Even the US government has gotten in on the action. Patent #6,630,507 was awarded to the US Department of Health and Human Services in 2003, and states that cannabinoids are neuroprotectants and anti-inflammitory agents, useful in the prevention and treatment of stroke, trauma, auto-immune disorders, Parkinson's, Alzheimer's and HIV dementia as well as many other diseases.”

“GW Pharmaceutical was granted a license to grow cannabis for medical research in 1998 and it's partner Bayer was granted a patent for Sativex in 2006. Sativex comes in a 5.5 ml spray bottle for $102 U.S. Dollars, which supplies about 51 sprays - enough for an average ten day supply. It is now available in Canada for MS and cancer pain, and has most recently become available in Britain and parts of Spain for use in the treatment of some other symptoms and syndromes.”

GW's position on intellectual property:

GW adopts an aggressive approach to securing intellectual property rights to protect techniques and technologies involved in the development programme. Protection is sought in the areas listed below:

• Plant variety rights
• Methods of extraction patents
• Drug delivery patents
• Patents on compositions of matter for delivery of cannabis
• Methods of use patents
• Design copyright on devices
• Trademarks

In the last few years our intellectual property portfolio has developed considerably. The patent portfolio has more than doubled in size and comprises 42 patent families, within these families there are numerous granted patents both in the UK and in various territories around the world. GW has also developed a trademark portfolio of 21 UK registered trademarks with equivalent marks registered in many other territories around the world. GW also holds nine registered design rights and nine plant variety rights.

...MORE HERE...

Prop 19 - the Hidden Agenda pt2

...pt1 (where we find Monsanto's Grubby Hands pulling the Prop 19 strings via the Drug Policy Alliance) HERE...

...pt2 Meet Dr Frankenbeanstein...

Are your expensive Dutch female seeds hard to clone, or when you try to breed them, all you get are hermaphrodites?

Thank Dr Frankenbeanstein, aka the Skunkman, real name David Watson.

A bit of history:
At a 1997 Vancouver Hemp conference, Watson spoke of his research. His main focus was to stop growers from cloning nor being able to create any seeds, from strains being bred in Amsterdam. The funding for this research came partially from the Dutch Government, the rest from DEA. Watson had been busted for growing in Santa Cruz California 3-20-85 and resurfaced in Amsterdam to start his seed company Cultivator’s Choice. DEA supported the Skunkman’s application for a license to grow for research in Holland, even though they should have been extraditing him back to Cali for his 1985 in Santa Cruz grow bust! DEA endorsement was so strong that he was the first to be granted a permit in Holland when several universities and domestic research groups with PHD’s and legitimate reasons for research were denied! The Dutch government even supplied three greenhouses for Dr. Frankenbeanstein to do his heinous experiments, while normal Dutch growers lost all their equipment and had to serve murder-like sentences at that time! Dutch seed companies have become the Monsanto of the cannabis seed industry, and hope to make us all seed junkies at $20 a seed.!

The license gave Hortapharm/Skunkman/DEA control over what researchers are allowed access to pedigreed seeds of predictable quality! The object is to patent up every possible combination of cannabinoids and terpenes with efficacy for every possible disease they can treat, and every possible genetic sequence! Once ready to make the move, they will shut down every medical cannabis grower for patent fraud, and those they can’t will be run out when they produce a more effective product for significantly less than $250 an ounce the growers are getting! The Skunkman’s company Hortapharm, is the only private organization approved by the Drug Enforcement Agency to supply genetics to researchers to this day!

Dr Frankenbeanstein threatened Skunk magazine to have all Dutch advertizing cancelled, which amount to 60% of their revenue, after printing part one of this article! This is the complete article. Skunk, High Times, Cannabis Culture, Weed-World in reality are trade pamphlets, that support the continuing rip off of our cannabis community by Hortapharm/GW Pharm/DEA, and the Dutch Cannabis Industry.

The one beacon of truth telling is Treating yourself magazine in our community. My only claim to fame being that I have always been a general in Lord Shiva’s Ganja Army. Bom Shiva Bom Shankar Joe Pietri

King of Nepal

...FULL ARTICLE HERE...

Prop 19 - the Hidden Agenda pt1

The agenda of the government in its policies against Cannabis have always been to deprive the people access to the plant, while maintaining control over it for the governments own self-interest. This self-interest extends to a multitude of industries including the prison and military industry, the petroleum, timber, cotton, and pharmaceutical industries, as well as the entirety of the banking and corporate establishment which has become empowered through disconnecting people from their one true source of independence and sustenance, the Earth. Cannabis prohibition has served to redirect human evolution from that of a decentralized agrarian lifestyle and natural economy, to a centralized petro-chemical military dictatorship controlled through the artificial economic will of private banks and other trans-national corporate interests.

The next stage in continuing this control, is in the regulation, licensing and taxation of Cannabis cultivation and use through the only practical means available to the corporate system, which is through genetic engineering and patenting of the Cannabis genome.

To achieve this end, the foundation is already being laid in the form of California’s upcoming initiative on the 2010 ballot. This initiative is called Proposition 19: The Regulate, Control and Tax Cannabis Act of 2010.

The leading advocate for Proposition 19 is the organization known as the Drug Policy Alliance (DPA). The DPA is the leading organization spearheading the reform of Cannabis policies in the United States, and has been made up of some of the most powerful and influential characters in today’s global petro-bio-chemical-military-banking-industrial complex.

Some of the Directors of DPA include the following:

Paul Adolph Volcker is an Honorary Director of the Drug Policy Alliance (DPA) whose career is closely associated with that of the Federal Reserve Bank. He was president of the Federal Reserve Bank of New York from 1975-1979, governing board member of the Federal Reserve in 1979, and was Chairman of the Federal Reserve from 1979-1987.

Volcker is believed to be a member of the Council on Foreign Relations, and served as Undersecretary of the Treasury from 1969-1974 before his time with the Federal Reserve. Volcker is chairman of Wolfensohn & Co. and has ties to Chase Manhattan Bank. He is also linked to the Brookings Institute, as well as being an Honorary Trustee at the Aspen Institute, chairman of the Group of 30, and on the board of the Institute for International Economics.

Frank Charles Carlucci III is an Honorary Director of the Drug Policy Alliance (DPA) and has been a member of the Council on Foreign Relations since at least 1995. His government service included positions as Deputy Secretary of Defense from 1980-1982 and Deputy Director of the CIA from 1978-1980.

Carlucci is a director on United Defense Industries (the United States' largest defense contractor), which is owned by the Carlyle Group, a merchant bank based in Washington, D.C., of which Carlucci is the chairman. Carlucci joined Carlyle in 1989.

Before returning to Government service, Carlucci was Chairman and CEO of Sears World Trade, a business he joined in 1983. He was President Ronald Reagan's National Security Advisor in 1987 and Secretary of Defense from 1987 to 1988.

Nicholas Katzenbach is an Honorary Director of the Drug Policy Alliance (DPA) and became General Counsel of the IBM Corporation from 1969 until 1986.

Mathilde Krim is a standing Director of the Drug Policy Alliance (DPA) and was a Trustee for the Rockefeller Foundation in 1980.

George Soros is a standing Director of the Drug Policy Alliance (DPA) and is Chairman of Soros Fund Management. Soros was among the highest paid hedge fund managers in 2009, taking home about $3.3 billion. At the end of 2009, he owned about $6.95 billion distributed among 697 stocks.

Soros’ top 5 investment shareholdings are in gold, Petrobras petroleum company, Hess Corp petroleum company, Monsanto corporation, Citigroup Inc., and Suncor Energy Inc.(petroleum company).

That’s right, George Soros, who is famous for being one of the most powerful and influential persons in world economics and whose speculations alone are said to have ‘broke the Bank of England‘, is one of the key directors for the organization that is leading the charge to regulate, control and tax Cannabis in California. All the while George Soros is one of the major shareholders in the worlds largest GM Seed bio-technology corporation known as Monsanto.

The Monsanto corporation brought you things like Agent Orange, Terminator Seeds, Monsantos Round-up ready Herbicide, and Genetically Modified and Patented Organisms made from Soybean, Corn, and Cotton to name a few. Genetically engineered crops entered the market in 1996 and to this day around 90% of all Soy, Corn, and Cotton grown in the U.S. have been Genetically Engineered and patented by a handful of bio-chemical corporations, with Monsanto owning 90% of all GMO patents.

The value of the Cannabis plant as an industry, without factoring in the value of Cannabis as a food or medicine, was estimated to be in the billions in 1938 by an article published by Popular Mechanics Magazine at that time, so its no wonder why one of Monsanto’s major shareholders would have in interest in advocating for one of the main tenants of prop 19, which is to “Make cannabis available for scientific, medical, industrial, and research purposes” and to “adopt a statewide regulatory system for a commercial cannabis industry”. Prop 19 is doing nothing less then opening the floodgates for Monsanto and other petro-chemical, GMO seed and pharmaceutical corporations to commercialize, regulate, control and tax Cannabis through genetic engineering, patenting and licensing.

...for FULL ILLUMINATING STORY go HERE...